World's Best Scientists 2026 revealed!
Award Badge
Medicine
Germany
2026

D-Index & Metrics

Medicine

D-Index
141
Citations
93320
World Ranking
1595
National Ranking
79

Research.com Recognitions

  • 2026 - Research.com Medicine in Germany Leader Award
  • 2023 - Research.com Medicine in Germany Leader Award

Overview

Claus Garbe is affiliated with the University of Tübingen in Germany and has contributed extensively to the field of medical research, particularly in oncology and dermatology. Their scholarly output includes a significant number of publications focused on melanoma, nonmelanoma skin cancers, and cancer immunotherapy.

The main fields of study in which Claus Garbe has published are Medicine and Biochemistry, Genetics and Molecular Biology. More specifically, their research spans subfields such as Oncology, Molecular Biology, Epidemiology, Dermatology, and Immunology.

Claus Garbe's work addresses a variety of key topics, including:

  • Cutaneous Melanoma Detection and Management
  • Melanoma and MAPK Pathways
  • Nonmelanoma Skin Cancer Studies
  • Cancer Immunotherapy and Biomarkers
  • CAR-T cell therapy research
  • Immunotherapy and Immune Responses
  • Cutaneous lymphoproliferative disorders research

Their recent notable publications include:

  • "European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022," published in 2022 in the European Journal of Cancer
  • "European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022," published in 2022 in the European Journal of Cancer
  • "Epidemiology of Skin Cancer: Update 2019," published in 2020 in Advances in experimental medicine and biology
  • "European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment," published in 2020 in the European Journal of Cancer
  • "Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial," published in 2021 in The Lancet Oncology

Claus Garbe frequently collaborates with several researchers in the field. Their most common co-authors include Ulrike Leiter, Thomas Eigentler, Axel Hauschild, Teresa Amaral, and Ralf Gutzmer.

The scientist's contributions frequently appear in prominent journals such as the European Journal of Cancer, JDDG Journal der Deutschen Dermatologischen Gesellschaft, Journal of the European Academy of Dermatology and Venereology, Cancers, and Aktuelle Dermatologie.

Best Publications

  • Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

    Paul B. Chapman;Axel Hauschild;Caroline Robert;John B. Haanen

  • Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

    Caroline Robert;Luc Thomas;Igor Bondarenko;Steven O'Day

  • Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

    Keith T. Flaherty;Caroline Robert;Peter Hersey;Paul Nathan

  • Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma

    James Larkin;Paolo A. Ascierto;Brigitte Dréno;Victoria Atkinson

  • Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group

    K T Flaherty;C Robert;P Hersey;P Nathan;P Nathan

  • Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

    G.V. Long;D. Stroyakovskiy;H. Gogas;E. Levchenko

  • Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

    Georgina V. Long;Georgina V. Long;Daniil Stroyakovskiy;Helen Gogas;Evgeny Levchenko

  • Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

    Grant A McArthur;Paul B Chapman;Caroline Robert;James Larkin

  • Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.

    Caroline Robert;Jean J Grob;Daniil Stroyakovskiy;Boguslawa Karaszewska

  • Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.

    Paolo A Ascierto;Grant A McArthur;Grant A McArthur;Brigitte Dréno;Victoria Atkinson

  • Epidemiology of melanoma and nonmelanoma skin cancer--the role of sunlight.

    Ulrike Leiter;Claus Garbe

  • Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

    Reinhard Dummer;Paolo A Ascierto;Helen J Gogas;Ana Arance

  • Dermcidin: a novel human antibiotic peptide secreted by sweat glands.

    Birgit Schittek;Rainer Hipfel;Birgit Sauer;Jürgen Bauer

  • Melanoma epidemiology and trends.

    Claus Garbe;Ulrike Leiter

  • Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma

    Antoni Ribas;Richard Kefford;Margaret A. Marshall;Cornelis J.A. Punt

  • Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma

    Axel Hauschild;Sanjiv S. Agarwala;Uwe Trefzer;David Hogg

  • Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma

    Jason Chesney;Igor Puzanov;Frances Collichio;Parminder Singh

  • Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial

    Ulrike Leiter;Rudolf Stadler;Cornelia Mauch;Werner Hohenberger

  • Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects

    Claus Garbe;Thomas K. Eigentler;Ulrich Keilholz;Axel Hauschild

  • Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.

    G. V. Long;K. T. Flaherty;D. Stroyakovskiy;H. Gogas

Frequent Co-Authors

Dirk Schadendorf
Dirk Schadendorf University of Duisburg-Essen
Axel Hauschild
Axel Hauschild Kiel University
Reinhard Dummer
Reinhard Dummer University of Zurich
Paolo A. Ascierto
Paolo A. Ascierto National Institutes of Health
Ralf Gutzmer
Ralf Gutzmer Hannover Medical School
Keith T. Flaherty
Keith T. Flaherty Harvard University
Caroline Robert
Caroline Robert University of Paris-Saclay
James Larkin
James Larkin Royal Marsden NHS Foundation Trust
Birgit Schittek
Birgit Schittek University of Tübingen

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students considering healthcare careers beyond traditional medical school, there are many flexible online degree options. Nursing professionals, for example, can transition quickly from a Bachelor of Science in Nursing to an advanced nurse practitioner role through bsn to np programs online. These programs open doors to specialized fields such as psychiatric mental health.

If you're interested in healthcare leadership or management, earning a health administration degree online is an affordable and accessible option. Many students go on to pursue advanced credentials through online mha programs affordable, which prepare graduates for high-level roles in hospitals, clinics, and healthcare systems.

For nurses aiming for the highest clinical or leadership positions, the best online dnp programs offer a streamlined path to doctoral-level practice. These programs are designed for working professionals seeking flexibility and affordability. Exploring these related pathways can help you find the right fit for your healthcare career ambitions.

Best Scientists Citing Claus Garbe

Trending Scientists